NCT04798898Recruiting
Improving Survival of COlorectal LIver Metastases by RFA-mediated Immunostimulation
Source: ClinicalTrials.gov · Last updated 5 Dec 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
To examine radio frequency ablation as a treatment supplement to stimulate immunogenicity and improve survival for patients undergoing curative-intent surgery for colorectal liver metastases.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- First submitted
- 9 Mar 2021
- Start date
- 14 Nov 2022
- Primary completion date
- 1 Jun 2025
- Lead sponsor
- University of Aarhus
- Diseases
- Colorectal cancer
- NCT number
- NCT04798898
What you commit to
- Study type: Interventional
- Planned participants: 200
- From 14 Nov 2022 to the primary completion date, 1 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Other malignant diseases within 5 years prior to diagnosis
- Prior RFA treatment
Other
- Liver cirrhosis
- Extrahepatic metastases that can not be addressed curatively
Who the study is looking for
- Patients with colorectal liver metastases planned for resection
- At least one tumor size \>=3cm
- Performance status 0-1
Age in the registry: 18 years to 99 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Aarhus University Hospital, Department of Surgery Coordinator of this site? Confirm its status | Aarhus | Denmark | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.